Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
The appointments will add to the well-diversified experience that currently exists on the PPL board.
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
Company is investing more than €100 million in the expansion of the Halle site
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The AICVD tool can predict the risk of cardiovascular disease.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Subscribe To Our Newsletter & Stay Updated
